NeuroSearch's revised results show Huntington's drug failed in Phase III
This article was originally published in Scrip
Executive Summary
NeuroSearch's Huntington's disease candidate Huntexil (pridopidine), previously hailed as a Phase III success, did not in fact meet its primary endpoint, revised data show.